Publications by authors named "Linda Rink"
Article Synopsis
- Sirolimus may enhance the effects of sunitinib against tumors by disrupting key signaling pathways and reducing tumor growth.
- The study evaluated different dosing regimens for this combination therapy in 18 patients, adjusting sunitinib's dosage due to significant side effects experienced early on.
- Despite some patients tolerating multiple treatment cycles, there were notable adverse effects, including fatigue and one severe case of interstitial pneumonitis, highlighting the need for careful monitoring.
Characterization of residual β cell function in long-standing type 1 diabetes.
Diabetes Metab Res Rev
February 2014
Background: Some patients with long-standing type 1 diabetes (T1D) maintain detectable levels of C-peptide. The quantitative and qualitative aspects of insulin secretion in these subjects have not been assessed, but may shed light on the basis for maintained β cell function. Our objective was to characterize insulin secretion in subjects with varying duration of T1D.
View Article and Find Full Text PDFOBJECTIVE Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from the gastrointestinal tract. Treatment with GLP-1 analogs has proven to be of clinical use for patients with type 2 diabetes. Patients with type 1 diabetes, particularly those with residual β-cell function, may also respond to treatment, but the acute metabolic effects of GLP-1 analogs on these patients in reaction to both oral and intravenous glucose challenges are not well understood.
View Article and Find Full Text PDF